

What is the LIGHTBEAM-01A Study testing?

This study is testing the investigational study drug, zilovertamab vedotin, in children, teens, and young adults who have certain advanced blood cancers and solid tumors.

Researchers want to:

1. Test the safety of zilovertamab vedotin.
2. See how well zilovertamab vedotin works.
3. See for how long zilovertamab vedotin works.
4. Measure what happens as zilovertamab vedotin goes through the body.

Who can join the study?

Your child may be considered if they*:

- Are 6 months to 18 years of age (up to 25 years for Ewing sarcoma).
- Have B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, neuroblastoma, or Ewing sarcoma.
- Have advanced cancer that has come back after treatment, has not responded to treatment, or for which there are no effective treatment options.

*Additional criteria apply.

Thank you for considering the LIGHTBEAM-01A Study.

Clinical studies are research studies that help doctors find out if study drugs (alone or with other treatments) are safe and if they can help prevent, find, or treat diseases or conditions.

Participation in a clinical study is voluntary, and you and your child can leave at any time.

[QR code]

Scan the code or visit
[www.site.com].





Understanding the **LIGHTBEAM-01A** Study



A clinical research study for
children, teens, and young adults
with certain advanced cancers

Study overview - Adult caregivers

What happens during the study?

There are 3 main phases to this study. The entire study lasts about 5 years.

Screening Period

To see if your child qualifies, the study doctor will collect information about your child's health and run some tests.

Study Treatment Period

Your child will have visits about every 3 weeks to receive the investigational study drug and have tests to monitor their health. At the start of the Study Treatment Period, your child will visit the study site more frequently for tests.

Follow-up Period


Your child will have 1 visit about 30 days after stopping the investigational study drug. Your child's remaining study visits will depend on whether or not their cancer grew while taking the investigational study drug or if they switch to a different treatment.

What study drug will my child receive?

All children in the study will receive the investigational study drug, zilovertamab vedotin.



Zilovertamab vedotin is given every 3 weeks as an intravenous (IV) infusion, which means it is given slowly through a vein.



What tests will my child have?

Your child will have tests to check their health and to see how their cancer is responding to the investigational study drug. Your child will not have every test at each visit.



Physical exam



Vital signs



Heart activity



Heart imaging



Blood tests



Urine test



Tumor scans



Cancer assessments

For more information on the LIGHTBEAM-01A Study, contact

at

and visit [www.site.com].

[QR code]